Quince Therapeutics (QNCX) Competitors $1.76 -0.02 (-1.12%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.80 +0.03 (+1.99%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNCX vs. KRRO, KMDA, IVVD, AURA, REPL, LBRX, LRMR, ANNX, DMAC, and EDITShould you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Korro Bio (KRRO), Kamada (KMDA), Invivyd (IVVD), Aura Biosciences (AURA), Replimune Group (REPL), LB Pharmaceuticals (LBRX), Larimar Therapeutics (LRMR), Annexon (ANNX), DiaMedica Therapeutics (DMAC), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry. Quince Therapeutics vs. Its Competitors Korro Bio Kamada Invivyd Aura Biosciences Replimune Group LB Pharmaceuticals Larimar Therapeutics Annexon DiaMedica Therapeutics Editas Medicine Korro Bio (NASDAQ:KRRO) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk. Do analysts prefer KRRO or QNCX? Korro Bio presently has a consensus price target of $86.83, indicating a potential upside of 127.97%. Quince Therapeutics has a consensus price target of $8.14, indicating a potential upside of 362.66%. Given Quince Therapeutics' higher possible upside, analysts plainly believe Quince Therapeutics is more favorable than Korro Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Korro Bio 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00Quince Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.91 Is KRRO or QNCX more profitable? Korro Bio's return on equity of -61.51% beat Quince Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Korro BioN/A -61.51% -42.87% Quince Therapeutics N/A -187.49%-42.47% Which has more volatility and risk, KRRO or QNCX? Korro Bio has a beta of 2.89, indicating that its stock price is 189% more volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Do insiders and institutionals believe in KRRO or QNCX? 13.2% of Korro Bio shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 4.6% of Korro Bio shares are held by company insiders. Comparatively, 20.3% of Quince Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, KRRO or QNCX? Quince Therapeutics has lower revenue, but higher earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKorro Bio$2.27M157.56-$83.58M-$9.75-3.91Quince TherapeuticsN/AN/A-$56.83M-$1.09-1.61 Does the media refer more to KRRO or QNCX? In the previous week, Korro Bio and Korro Bio both had 1 articles in the media. Korro Bio's average media sentiment score of 1.91 beat Quince Therapeutics' score of 1.89 indicating that Korro Bio is being referred to more favorably in the media. Company Overall Sentiment Korro Bio Very Positive Quince Therapeutics Very Positive SummaryQuince Therapeutics beats Korro Bio on 8 of the 13 factors compared between the two stocks. Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNCX vs. The Competition Export to ExcelMetricQuince TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$95.61M$3.43B$6.23B$10.66BDividend YieldN/A2.27%5.71%4.82%P/E Ratio-1.6124.2730.2030.21Price / SalesN/A489.03590.34132.63Price / CashN/A45.5737.0161.44Price / Book2.5510.4012.046.60Net Income-$56.83M-$52.62M$3.32B$276.82M7 Day Performance-5.38%2.09%1.89%2.58%1 Month Performance7.98%12.32%7.68%3.76%1 Year Performance62.96%14.12%56.01%33.84% Quince Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNCXQuince Therapeutics3.5771 of 5 stars$1.76-1.1%$8.14+362.7%+47.9%$95.61MN/A-1.6160Positive NewsKRROKorro Bio2.6277 of 5 stars$46.35+10.0%$86.83+87.3%-44.1%$395.83M$2.27M-4.7570Gap UpKMDAKamada4.6783 of 5 stars$7.08+4.9%$13.00+83.6%+29.3%$388.16M$160.95M20.82360News CoveragePositive NewsIVVDInvivyd4.1929 of 5 stars$1.97+13.2%$5.14+160.8%+125.5%$373.07M$25.38M-2.14100Positive NewsAURAAura Biosciences2.0482 of 5 stars$6.06+6.9%$20.50+238.3%-47.9%$352.22MN/A-3.0950REPLReplimune Group4.3808 of 5 stars$8.94+98.7%$11.00+23.0%-26.4%$351.25MN/A-2.76210Analyst RevisionHigh Trading VolumeLBRXLB PharmaceuticalsN/A$16.00+2.6%$30.50+90.6%N/A$350.11MN/A0.0016Quiet Period ExpirationLRMRLarimar Therapeutics3.2657 of 5 stars$4.35+3.6%$16.71+284.2%-47.1%$347.67MN/A-2.7930Upcoming EarningsGap UpANNXAnnexon2.045 of 5 stars$3.16+0.3%$12.50+295.6%-56.9%$346.14MN/A-2.4560Analyst ForecastGap UpDMACDiaMedica Therapeutics1.0866 of 5 stars$6.77+2.9%$12.33+82.2%+58.7%$340.11MN/A-9.8120News CoverageAnalyst ForecastEDITEditas Medicine4.4369 of 5 stars$4.14+9.8%$5.10+23.2%+17.0%$339M$32.31M-1.45230Analyst Forecast Related Companies and Tools Related Companies Korro Bio Alternatives Kamada Alternatives Invivyd Alternatives Aura Biosciences Alternatives Replimune Group Alternatives LB Pharmaceuticals Alternatives Larimar Therapeutics Alternatives Annexon Alternatives DiaMedica Therapeutics Alternatives Editas Medicine Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNCX) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QNCX Stock Alerts